FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

How Long Does Retatrutide Take to Work? Results at 24, 48, 80 and 104 Weeks

Empty body composition research suite with a scanner table under a slim arm beside tall windows, low morning sun across the floor and lab benches behind a glass wall

Retatrutide starts working with the first weekly injection and shows on the scale within a month. Weight loss reaches double digits around week 12 and keeps climbing for more than a year, because the dose rises in four-week steps.

The trials put a number on every stage. In Phase 2, the group headed for 12mg was about 3% lighter by week 4 and 17.5% by week 24, and still losing when the trial ended at week 48. Phase 3 carried the clock to two years, where people who began heavier averaged 30.3% below their starting weight.

Simms Research sells it as Retatrutide (GLP-3), a freeze-dried research powder. Why it carries a GLP number is in What Is GLP-3 (Retatrutide)?

Retatrutide weight loss timeline at a glance

The top-dose averages below come from four trials; the week 4 and week 12 figures are read from the Phase 2 trial’s published weight curve (Jastreboff, New England Journal of Medicine, 2023).

WeekAverage weight loss, top doseTrialWhat else had moved
4About 3%Phase 2, 2mg startDose steps up from 2mg to 4mg
12About 10%Phase 2Full 12mg dose reached this week
2417.5%Phase 2Liver fat down 82%, heart rate at its peak
4016.8%TRANSCEND-T2D-1, type 2 diabetesStill falling when the trial ended
4824.2%Phase 2No plateau yet
6828.7%TRIUMPH-4, knee osteoarthritisKnee pain down by about three-quarters
8028.3%TRIUMPH-1Two in three below the BMI line for obesity
10430.3%TRIUMPH-1 extension, BMI 35 or more2 points past the 80-week mark

The Phase 3 figures are Lilly’s averages for people who stayed on the drug. Counting dropouts too, the published results are 25.0% for TRIUMPH-1 at 80 weeks (Jastreboff, New England Journal of Medicine, 2026), 23.7% for TRIUMPH-4 at 68 weeks (Schnitzer, New England Journal of Medicine, 2026) and 15.3% for TRANSCEND-T2D-1 at 40 weeks (Bajaj, The Lancet, 2026).

How long does retatrutide take to kick in?

From the first injection, at a low level. The full weekly effect takes about a month to build, and the four-week dose steps add to it from there.

Retatrutide has a half-life of about six days (Urva, The Lancet, 2022). Roughly 45% of each dose remains when the next one goes in, so levels stack for the first four or five weeks before they settle. A single dose is enough to register: in the first human study, one injection lowered body weight, and the drop could still be measured on day 43 (Coskun, Cell Metabolism, 2022).

The parts of the molecule run on different clocks. The GLP-1 side slows the stomach and quiets hunger from the first weeks; the glucagon side, which raises energy use and pulls fat out of the liver, shows over months.

Phase 3 climbed more slowly, from 2mg through 4, 6 and 9mg, so its 12mg groups reached full dose at week 17, four weeks later than in Phase 2, and its 4mg groups stopped climbing at week 5 (Giblin, Diabetes, Obesity and Metabolism, 2026).

Small bright weigh room with a flat platform scale on a pale floor, a white chair in the corner and a folded towel on a wall shelf in window light

Retatrutide week by week: the first 24 weeks

The early numbers come from the Phase 2 obesity trial, which randomized 338 adults to placebo or one of six retatrutide schedules for 48 weeks.

The scale moves in month one and fastest in months two to four. The Phase 2 curve for the group that stepped from 2mg to 12mg shows dose and weight loss climbing together:

WeekWeekly dose that monthAverage weight lossPlacebo
42mgAbout 3%About 1%
84mgAbout 6%About 1%
128mgAbout 10%About 1%
1612mgAbout 13%About 1.5%
2012mgAbout 15%About 1.5%
2412mg17.5%1.6%

Each four-week step adds roughly three more points. Groups started straight on 4mg were about 5% down at week 4, so a bigger first dose pulls the early weeks forward, and at week 24 those groups still led their 2mg-start twins by one to two points. Every arm, placebo included, had diet and activity counseling throughout.

How much weight loss per week on retatrutide

About 2 lb a week for the first three months from a 250 lb start, then less each stretch after: about 1.6 lb a week from week 12 to 24, 0.7 lb from week 24 to 48 and 0.3 lb from week 48 to 80. As a share of starting weight that is about 0.8% a week at first, then 0.65%, 0.3% and 0.1%, with the last stretch bridging the Phase 2 year and TRIUMPH-1’s 80 weeks.

No single week looks like the average. A weigh-in swings with water and salt, so the four-week trend is the number to hold against the trials.

Retatrutide results at 24 weeks

17.5% on the schedule ending at 12mg, 17.3% on 8mg, 12.9% on 4mg and 7.2% on 1mg, against 1.6% on placebo, at the Phase 2 trial’s main endpoint.

The liver moves faster than the scale. In 98 trial participants who started with fatty liver, liver fat fell by 82.4% on 12mg and 81.4% on 8mg by week 24, and 86% of the 12mg group were back in the normal range, against none on placebo (Sanyal, Nature Medicine, 2024).

Appetite was scored in the Phase 2 diabetes trial. At week 24, people on 4mg or more reported bigger drops in hunger, overall appetite and how much they expected to eat than people on placebo, and by week 36 the fall in hunger tracked the weight lost (Kanu, Diabetes, Obesity and Metabolism, 2025).

Retatrutide results at 48 weeks

24.2% on 12mg, 22.8% on 8mg, 17.1% on 4mg and 8.7% on 1mg, against 2.1% on placebo. Everyone on 8mg or 12mg lost at least 5%, and a quarter of the 12mg group lost 30% or more. On 12mg, 93% lost 10% or more and 83% lost 15% or more; on 8mg, 91% and 75%; on 4mg, 75% and 60%. On placebo, 9% and 2% did.

The curves were still pointing down when treatment stopped at week 48, with no plateau reached (Jastreboff, New England Journal of Medicine, 2023). The second half of the year added about 7 points on 12mg, under half of what the first half did.

Dose sets the speed. The 12mg schedule reached 17.5% by week 24; the 4mg groups needed until week 48 to reach 17.1%. Blood sugar followed the weight: 72% of those on retatrutide who began with prediabetes had normal readings at week 48, against 22% on placebo. Step-by-step dosing for each target is in the retatrutide dosage chart.

Retatrutide results for men and women

Women lost more, and so did people who started heavier. On 12mg, women averaged 26.6% at 48 weeks and men 21.9%; people with a starting BMI of 35 or more averaged 26.4% against 21.5% below 35. Both gaps held at 8mg. What women reported along the way is covered in side effects of retatrutide for women.

Long white lab bench with a series of white racks of capped sample tubes, some holding pale straw-coloured serum, receding toward a bright window

Retatrutide results at 80 weeks

28.3% on 12mg, 25.9% on 9mg and 19.0% on 4mg, against 2.2% on placebo, in TRIUMPH-1’s 2,339 adults without diabetes, reported by Lilly on May 21, 2026. That is 70.3 lbs on average at the top dose, and 45.3% of that group lost at least 30%.

Set beside the Phase 2 year, the slope is gentle by now. Retatrutide’s 48-week mark was 24.2%; another 32 weeks added roughly four points. TRIUMPH-4, which ended at week 68 in people with knee osteoarthritis, finished at 28.7%, within half a point of TRIUMPH-1’s 80-week figure.

Other 80-week trials landed lower in harder groups: 22.6% with heart disease (TRIUMPH-3) and 20.9% in type 2 diabetes against 9.4% on Ozempic 2mg (TRANSCEND-T2D-2, October 28, 2026). Every result, dose by dose, is in the retatrutide vs tirzepatide comparison.

Blood pressure, cholesterol and waist by week 80

They moved with the weight. By week 80 in TRIUMPH-1, retatrutide had lowered systolic blood pressure by up to 12.3 mmHg, triglycerides by up to 41.0% and waist size by up to 9.5 inches. In the 48-week Phase 2 trial, hs-CRP, a marker of inflammation, fell 54.8% (Ruotolo, Diabetes, Obesity and Metabolism, 2026).

Retatrutide results at 104 weeks

30.3%, or 85.0 lbs, on 12mg, in people who started with a BMI of 35 or more. TRIUMPH-1 kept 532 of them going for 24 weeks past the main trial on the highest dose each tolerated, and they finished two points past the whole trial’s 80-week average (Lilly, May 21, 2026).

The extension also shows a late start. Its placebo group was switched onto retatrutide at week 80 without being told and stood 18.9% below its starting weight by week 104, counting everyone who entered. Placebo had taken off 3.9% by week 80, so 24 weeks of the drug added about 15 points, close to the Phase 2 pace over its first six months.

Starting low did not cap the result: people who spent the main trial on 4mg moved up in the extension and reached 27.9% by week 104.

Does retatrutide work faster than tirzepatide or semaglutide?

Yes, going by each drug’s own trials. People who stayed on semaglutide 2.4mg were 10.6% lighter after 20 weeks (Rubino, JAMA, 2021); retatrutide’s 12mg schedule was at about 15% by then. Tirzepatide took 88 weeks to reach 25.3% (Aronne, JAMA, 2024); retatrutide reached 24.2% in 48.

Counting everyone who started, semaglutide finished STEP 1 at 14.9% after 68 weeks (Wilding, New England Journal of Medicine, 2021), tirzepatide finished SURMOUNT-1 at 20.9% after 72 (Jastreboff, New England Journal of Medicine, 2022) and retatrutide finished TRIUMPH-1 at 25.0% after 80. Separate trials rank the drugs rather than measure the gap exactly. The direct race with tirzepatide, TRIUMPH-5 in 800 adults, is due to finish late in 2026.

Why retatrutide keeps working past a year

The glucagon receptor. GLP-1 and GIP mostly cut how much gets eaten, and weight loss on them slows as a lighter body burns less. Glucagon adds energy use: in obese mice, it raised energy expenditure on top of retatrutide’s drop in food intake (Coskun, Cell Metabolism, 2022).

Most of what comes off is fat. In a 36-week body-scan substudy in type 2 diabetes, fat mass fell 26.1% on 8mg and 23.2% on 12mg, against 4.5% on placebo, with lean mass making up a share of the loss similar to other obesity drugs (Coskun, The Lancet Diabetes and Endocrinology, 2025).

Retatrutide results with type 2 diabetes

Slower and smaller on the scale, and blood sugar moves first. In the first 12-week study in type 2 diabetes, the schedule that climbed to 12mg took off 8.96 kg more than placebo (Urva, The Lancet, 2022).

In the Phase 2 diabetes trial, A1C had fallen by 2.02 points on 12mg at week 24, against none on placebo, while body weight was still on its way to 16.9% at week 36 (Rosenstock, The Lancet, 2023). The first Phase 3 diabetes trial, TRANSCEND-T2D-1, reached 16.8% at 40 weeks on 12mg with weight loss not yet levelling off, and up to 46% of participants reached an A1C below 5.7%, the normal range.

Over the full 80 weeks, TRIUMPH-2 reached 20.8% in people with obesity and type 2 diabetes, or 18.8% counting dropouts (Bellido, The Lancet, 2026), against 28.3% in TRIUMPH-1 without it. The clock runs the same way, just with a lower finish.

Round white table by a tall window with a glass of water, a white cup and a white teapot, a pale blue chair and lab benches out of focus behind glass

When retatrutide side effects start and settle

They cluster around the dose steps and ease once the dose holds. In Phase 2, stomach side effects showed up mainly while the dose was being raised, were mostly mild to moderate and were partly avoided by starting at 2mg rather than 4mg (Jastreboff, New England Journal of Medicine, 2023), and in TRANSCEND-T2D-1 they subsided over time (Bajaj, The Lancet, 2026).

Across TRIUMPH-1’s 80 weeks, nausea was reported by 42.4% of people on 12mg and 28.6% on 4mg, against 14.8% on placebo; diarrhea by 32.0% and 25.2%, against 13.5%; vomiting by 25.3% and 10.6%, against 4.8%. Stopping over side effects ran from 4.1% on 4mg to 11.3% on 12mg, with placebo at 4.9%. Dysesthesia, a tingling or over-sensitive feeling on the skin, came up in 5.1% to 12.5% against 0.9%, and most cases cleared while people kept taking it.

Heart rate keeps its own calendar. It rose with the dose in Phase 2, peaked at week 24 and was lower again at weeks 36 and 48.

How long retatrutide takes to work after switching from tirzepatide

The first month is a step down, not a jump. Every retatrutide trial began at 2mg, a smaller effect than a top tirzepatide dose, and none has tested a switch: Phase 3 took only people whose weight had held within 5kg for the 90 days before screening (Giblin, Diabetes, Obesity and Metabolism, 2026).

The old drug fades on its own clock. Tirzepatide’s half-life is about five days, so about 38% of the last dose is left after seven days and 14% after fourteen. Started when the next tirzepatide dose was due, retatrutide builds over four or five weeks while the old one falls away.

The retatrutide dose that beat tirzepatide 15mg’s trial result, 9mg at 25.9% against 22.5%, arrives at week 13 on the Phase 3 ladder, so the first month after a switch says little about where it ends. No trial has yet enrolled people at a plateau on another drug. The steps are in the retatrutide dosage guide.

So how long does retatrutide take to work?

About a month to show on the scale, three months to reach double digits, six months for most of the result and a year or more for all of it.

About 3% down is a normal first month on the 2mg starter. Double digits arrive around week 12, and week 24’s 17.5% is more than half the final result. Then it slows: 24.2% at a year, 28.3% at 80 weeks and 30.3% at two years for people who started heavier. A lower dose runs the same curve more slowly, and type 2 diabetes flattens it.

Retatrutide for research from Simms Research

Simms Research’s Retatrutide (GLP-3) comes in 10mg ($84), 20mg ($129), 30mg ($159) and 60mg ($259) vials. Its July 16, 2026 certificate tested three vials at 99.611% purity and measured 10.68mg in a vial labelled 10mg, with endotoxin, heavy metal and microbial results included, posted under retatrutide lab results. The retatrutide calculator turns any weekly dose into syringe units for each vial size.

The sizes follow the Phase 3 ladder: four weeks at 2mg use one 10mg vial, four at 4mg a 20mg vial, four at 6mg a 30mg vial and four at 12mg 48mg of a 60mg vial, inside the 28 days a mixed vial keeps in the fridge. How to Reconstitute Retatrutide has the water for each size.

An order in before 5 PM Eastern leaves the same day, with FedEx 2-Day free over $200. Three vials take 5% off, six take 10%, and Simms Rewards points come with every order.

Frequently asked questions

How much weight can you lose in a month on retatrutide?

About 3% in the first month on the 2mg starting dose and about 5% on a 4mg start, going by the Phase 2 curve. From a 250 lb start, that is roughly 7 to 12 lbs.

Are retatrutide results permanent?

Not without the drug, going by its class. Retatrutide’s own stopping trial, TRIUMPH-6, runs to April 2028; on tirzepatide, people moved to placebo regained 14.0% of their body weight within a year (Aronne, JAMA, 2024). Can You Stop Retatrutide? covers what comes back.

When will retatrutide be available by prescription?

Lilly plans to file it with the FDA in the first quarter of 2027. The review clock and launch timing are in When Will Retatrutide Be FDA Approved?

Is Simms Research legit?

Simms Research is a US research supplier shipping from Florida. An independent ISO-certified lab checks each batch before it goes on sale, and the reports sit in its public lab results library. Its Free Delivery Guarantee covers lost, stolen or damaged parcels, and support answers by email and on 855-592-8507 on weekdays.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results